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E-mail address: tsakai@koto.kpu-m.ac.jp (T. Sakai)Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an endogenous cytokine that
induces apoptosis in malignant tumor cells. Here, we show for the ﬁrst time that lactobacilli induce
TRAIL production in human peripheral blood mononuclear cells (PBMC). Treatment with lactobacilli
induced TRAIL on the cell surface of PBMC and in culture medium. The TRAIL production induced by
lactobacilli partially depends on IFN-a and IFN-c. Lactobacilli treatment facilitated NK activity of
PBMC against prostate cancer cells. Moreover, TRAIL neutralization antibody efﬁciently prevented
the NK activity. Our results indicate that lactobacilli facilitate NK activity through TRAIL production,
and raise the possibility of a new TRAIL-based strategy against malignant tumors.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
selectively induces apoptosis in cancer cells in vitro and in vivo
[1,2]. Thus, recombinant TRAIL protein and agonistic antibodies
for TRAIL receptors are undergoing clinical trials as treatments
against malignant tumors [3,4]. TRAIL induces apoptosis through
interaction with death receptor (DR) 5 or DR4. The TRAIL-DR4/5
pathway is considered to be essential for these anti-tumor effects
[5]. TRAIL is also expressed endogenously as a membrane protein
and as a soluble protein in immunocytes [6]. Endogenous TRAIL
plays an important role in the inhibition of carcinogenesis, since
TRAIL deﬁciency accelerates malignancies in mice [7]. Therefore,
not only recombinant TRAIL or agonistic antibodies for TRAILchemical Societies. Published by E
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.receptors but also the agents producing endogenous TRAIL are
promising for anti-cancer strategy.
Various species of lactobacilli have an important role in the
manufacturing of fermented products. It has been reported that
some fermented products have immunological effects [8]. More-
over, it has been reported that lactobacilli have also anti-cancer ef-
fects in vitro and in vivo [9,10]. Large-scale randomized clinical
studies have shown a possibility that a Lactobacillus (L.) casei prep-
aration may be promising for cancer prevention [11,12]. However,
little is known about the molecular mechanisms of the anti-tumor
effects of lactobacilli. In this study, we used the probiotic species
Lactobacillus plantarum, which has been used in the manufacturing
of pickles. There was a report that the daily intake of L. plantarum
augmented acquired immunity in healthy adults [13]. In mice, dai-
ly administration of this strain had an anti-tumor effect [14].
In this report, we show that L. plantarum induces TRAIL produc-
tion and enhances natural killer activity against cancer cells.
2. Materials and methods
2.1. Lactobacillus strains
L. plantarum S1, DB22, and DS41 were isolated from Japanese
pickles and routinely cultured for 24 h at 30 C in MRS mediumlsevier B.V. All rights reserved.
Fig. 1. PBMC stimulated with L. plantarum increase cell surface and soluble TRAIL. Human PBMC were isolated from blood of healthy volunteer and incubated (2  106/ml)
with L. plantarum (10 lg/ml) and IFN-a (1000 IU/ml) for 24 h. The ﬁgure represents results of one typical experiment of three experiments performed. (A) The cell surface
TRAIL expression was assayed by ﬂow cytometry. Filled histograms: control (no treatment); unﬁlled histograms: treated with L. plantarum S1. (B) The Y-axis represents the
geometric mean ﬂuorescence intensity (GMFI) of the cell populations in the histograms of (A). PBMC were treated with L. plantarum S1, DB22, or DS41, and IFN-a. (C) The
culture supernatant was assayed for soluble TRAIL by ELISA as described in Section 2. CT: no treatment. The values shown are means (n = 3); bars: ±S.D. *P < 0.05.
Fig. 2. PBMC from different individuals stimulated with L. plantarum increase cell surface and soluble TRAIL. Human PBMCwere isolated from blood of ﬁve healthy volunteers
and cultured (2  106/ml) with L. plantarum S1 (10 lg/ml) for 24 h. The ﬁgure represents results of one typical experiment of two experiments performed. (A) The cell surface
TRAIL expression was assayed by ﬂow cytometry. Filled histograms: control (no treatment); unﬁlled histograms: treated with L. plantarum S1. (B) The Y-axis represents GMFI
of the cell populations in the histograms of (A). (C) The culture supernatant was assayed for soluble TRAIL by ELISA as described in Section 2. CT: no treatment. The values
shown are means (n = 3); bars: ±S.D. *P < 0.05.
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Fig. 3. L. plantarum strains induce TRAIL expression at the total protein and mRNA
levels. Human PBMC were isolated from blood of healthy volunteer and cultured
(2  106/ml) with L. plantarum (10 lg/ml) for 24 h. (A) Western blotting of TRAIL in
L. plantarum-stimulated PBMC. PBMC were treated with L. plantarum S1, DB22,
DS41, and IFN-a. Western blot analysis was carried out with anti-TRAIL antibody.
To examine comparable loading, the same blot was probed with anti-GAPDH
antibody. (B) Quantitative real-time RT-PCR of TRAIL mRNA in L. plantarum-
stimulated PBMC. The internal control was b2-microglobulin. The ﬁgure represents
results of one typical experiment of three experiments performed.
M. Horinaka et al. / FEBS Letters 584 (2010) 577–582 579(Oxoid, Basingstoke, UK). The cultures were diluted to 1 mg/ml in
saline, and heated for 5 min at 95 C.
2.2. Cell culture
Human prostate cancer PC3 cells were maintained as previ-
ously described [15]. Normal human peripheral blood mononu-
clear cells (PBMC) were isolated as previously described [15].
PBMC were acquired from healthy volunteers after obtaining in-
formed consent.
2.3. Flow cytometric analysis for TRAIL or TRAIL receptors on the cell
surface
The monoclonal antibodies (mAb) used were as follows: phy-
coerythrin (PE)-conjugated mouse anti-human TRAIL mAb and
ﬂuorescein-isothiocyanate (FITC)-conjugated mouse anti-human
CD4 mAb (BD PharMingen, San Diego, CA), and FITC-conjugated
mouse anti-human CD56 mAb and mouse IgG1; PE-conjugated
mouse anti-human DR4, DR5, decoy receptor1 (DcR1), or DcR2
mAb, and mouse IgG1 (eBioscience, San Diego, CA). Both PBMC
and PC3 cells were incubated with ﬂuorochrome-conjugated
mAb for surface staining. Event acquisition and analyses were
performed using the CellQuest software (BD Bioscience) in a
FACSCalibur ﬂow cytometer (BD Bioscience). The expression of
cell surface protein was measured as the geometric mean
ﬂuorescence intensity (GMFI). Human IFN-a was purchased
from Dainippon Sumitomo Pharma (Osaka, Japan). Anti-human
IFN-a and IFN-c neutralizing mAbs were purchased from
eBioscience.
2.4. TRAIL-display system
PBMC were treated with the agent for 24 h, and cell surface
TRAIL expression was analyzed with PE-conjugated TRAIL mAb in
a FACSCalibur ﬂow cytometer.
2.5. Enzyme-linked immunosorbent assay (ELISA)
Cell-free supernatants were prepared by ﬁltration with a
0.22 lm membrane ﬁlter. Human TRAIL ELISA kit and human
IFN-c ELISA kit from Biosource (Camarillo, CA) were used accord-
ing to the manufacturer’s instructions.
2.6. Western blot analysis
Western blot analysis was carried out as previously described
[15]. Anti-TRAIL mAb (BD PharMingen) and anti-glycerlaldehyde-
3-phosphate dehydrogenase mAb (HyTest, Turku, Finland) were
used as primary antibodies.
2.7. RNA isolation and quantitative real-time RT-PCR
RNA isolation and quantitative real-time RT-PCR were carried
out as previously described [15]. The real-time quantitative
reverse transcription-PCR primer-probe sets for TRAIL mRNA
(Hs00234355_A1) and b2-microglobulin mRNA (Hs99999907_
A1) were purchased from Applied Biosystems.
2.8. 51Chromium release assay
51Chromium release assay carried out as previously described
[8]. Human recombinant DR5/Fc chimeric protein was
purchased from R&D Systems (Minneapolis, MN), and anti-hu-
man TRAIL neutralizing mAb (RIK-2) was purchased from BD
PharMingen.2.9. Statistical analysis
The data were analyzed using the Student’s t-test. Differences
were considered to be statistically signiﬁcant from the controls
at P < 0.05.
3. Results
3.1. L. plantarum induces cell surface and soluble TRAIL
To search for agents that can induce endogenous TRAIL, we used
a TRAIL expression display system as described in the Section 2.
We found that cell surface TRAIL was induced by the addition of
L. plantarum strain S1 (Fig. 1A). IFN-awas used as a positive control
[16]. To examine whether TRAIL is induced by only strain S1
among L. plantarum, we employed other strains (DB22 and
DS41). DB22, DS41, and S1 all possessed the ability to increase
TRAIL expression on the surface of PBMC (Fig. 1B). To further
examine the response of PBMC to L. plantarum stimulation, we next
investigated the release of soluble TRAIL by ELISA. Examination of
the supernatants from L. plantarum-stimulated PBMC demon-
strated that soluble TRAIL was markedly increased compared with
that from unstimulated PBMC (Fig. 1C). These results indicate that
L. plantarum increases cell surface and soluble TRAIL.
3.2. TRAIL induction by L. plantarum S1 is not donor-speciﬁc
To verify the above result, we investigated the effect of L.
plantarum using PBMC from ﬁve different healthy volunteers. The
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with L. plantarum S1 from all ﬁve donors (Fig. 2A and B). We next
investigated the release of soluble TRAIL from each PBMC by ELISA.
In the L. plantarum S1-stimulated PBMC, the amount of soluble
TRAIL was markedly increased compared with that from unstimu-
lated PBMC in all ﬁve donors (Fig. 2C). These results indicate that
the induction of TRAIL expression by L. plantarum stimulation is
general, although but the rate of the induction depends on each
individual.3.3. L. plantarum up-regulates TRAIL expression at the mRNA and
protein levels
Next, we examined how L. plantarum regulates the expres-
sion of TRAIL. We performed a Western blot analysis using
whole cell extracts from L. plantarum-stimulated PBMC
(Fig. 3A). All three strains of L. plantarum increased the amount
of TRAIL at the total protein level in PBMC. Furthermore, we
analyzed the TRAIL mRNA level after a L. plantarum treatment
by quantitative real-time RT-PCR. L. plantarum treatment in-
creased TRAIL mRNA expression about 4.3–7.0-fold compared
to unstimulated PBMC (Fig. 3B), suggesting that L. plantarum in-
duces TRAIL mRNA and protein.Fig. 4. The expression of membrane-bound TRAIL in NK cells and T cells by L. plantarum t
(2  106/ml) with L. plantarum (10 lg/ml) for 24 h. PBMC were labeled for CD56, CD4 and
percentage of TRAIL-positive cells in the CD56+ or CD4+ population. FITC- and PE-conjug
treatment. PE; phycoerythrin. FITC; ﬂuorescein isothiocyanate. The ﬁgure represents res3.4. L. plantarum induces TRAIL from natural killer cells and T helper
cells
Moreover, to investigate which subsets of PBMC induce TRAIL
following L. plantarum treatment, we examined the expression of
TRAIL in CD56 positive natural killer (NK) cells by ﬂow cytometry.
In unstimulated conditions, few TRAIL-positive cells were found
among the CD56+ NK cells (Fig. 4). After L. plantarum stimulation,
the number of TRAIL-positive cells was markedly increased to
30–35% of the CD56+ NK cells. In addition, we also conﬁrmed about
CD16 positive cells as NK cells. After L. plantarum stimulation, the
number of TRAIL-positive cells was markedly increased to 30–38%
of the CD16+ NK cells (Supplementary ﬁgure). However, the
remaining population also expressed cell surface TRAIL, and so
CD4 positive T helper cells were examined. L. plantarum stimula-
tion increased the TRAIL positive population to 14–21% of CD4+ T
helper cells. These results indicate that the cell surface TRAIL is en-
hanced in CD56+ NK cells and CD4+ T helper cells by L. plantarum.
3.5. TRAIL induction by L. plantarum partly depends on the production
of IFN-a and IFN-c from PBMC
We examined the mechanism by which L. plantarum induces
TRAIL. Previous reports showed that TRAIL is expressed on immu-reatment. Human PBMC were isolated from blood of healthy volunteer and cultured
TRAIL with speciﬁc antibodies. The numbers in the upper right portion represent the
ated mouse IgG1 isotype control antibodies were used as negative controls. CT: no
ults of one typical experiment of three experiments performed.
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administration of lactobacilli induced the release of IFN-c [18].
Therefore, we hypothesized that L. plantarum induces TRAIL
expression through IFN-a and/or IFN-c. We examined the involve-
ment of IFN-a and/or IFN-c in the expression of the TRAIL on the
surface of PBMC (Fig. 5A) and in the release of soluble TRAIL caused
by the L. plantarum (Fig. 5B). We used IFN-a- or IFN-c-speciﬁc neu-
tralizing monoclonal antibodies (mAb) to block IFN-a- or IFN-c-
activity. The both of IFN-a and -c neutralizing mAb signiﬁcantly
blocked the expression of the surface TRAIL and the release of sol-
uble TRAIL caused by the L. plantarum stimulation against PBMC.
Moreover, double neutralization of both types of interferon was
able to more completely attenuate the induction TRAIL expression
(Fig. 5). These results suggest that the TRAIL expression induced by
L. plantarum depends on IFN-a and -c. Previous reports showed
that immunocytes stimulated with IFN-a [16] or IFN-c [19] hadFig. 5. Involvement of IFN-a and IFN-c in the release of soluble TRAIL induced by
PBMC. Human PBMC were isolated from blood of healthy volunteer and cultured
(2  106/ml) with L. plantarum (10 lg/ml) for 24 h. PBMC were cultured with L.
plantarum with or without anti-human IFN-a and/or -c neutralizing mAb (10 lg/
ml). (A) Cell surface expression of TRAIL. The Y-axis represents GMFI of the cell
populations. (B) ELISA for TRAIL. PBMC were cultured with L. plantarum with or
without anti-human IFN-a and/or -c neutralizing mAb (10 lg/ml). The values
shown are means (n = 3); bars: ±S.D. *P < 0.05. CT: no treatment. The ﬁgure
represents results of one typical experiment of three experiments performed.the cytotoxicity against human cancer cells. In this case, it is pos-
sible that TRAIL might be one of the mechanisms.
3.6. L. plantarum-treated PBMC exert NK activity against cancer cells
that is TRAIL-dependent
To evaluate the anti-cancer effects of the TRAIL production by L.
plantarum-stimulation, we measured the NK activity against pros-
tate cancer PC3 cells. First, we investigated the expression of TRAIL
receptors on PC3 cells. PC3 cells abundantly expressed two DRs,
DR4 and DR5, but not two decoy receptors, DcR1 and DcR2, on
their surface (Fig. 6A). Next, we performed a 51Cr release assay.
The cytotoxicity of L. plantarum-stimulated PBMC against PC3 cells
was markedly increased compared with that of unstimulated
PBMC (Fig. 6B). Interestingly, the cytotoxicity of L. plantarum-stim-Fig. 6. L. plantarum-treatment facilitates NK activity against cancer cells. (A) Cell
surface expression of TRAIL. The ﬁlled histograms represent staining with isotype
monoclonal antibody, and the unﬁlled histograms represent staining with PE-
conjugated anti-DR4, anti-DR5, anti-DcR1, or anti-DcR2 mAb. (B) 51Cr release assay.
PBMC (effecter cells) were cultured with L. plantarum S1 for 24 h and then added to
51Cr-labeled PC3 cells (target cells) at the indicated E:T ratios. The cells were co-
incubated for 4 h, and the radioactivity was measured with a TopCount NXT system.
(d): no treatment, (s): L. plantarum S1-stimulated, (): L. plantarum S1-stimulated
with 10 lg/ml TRAIL neutralization antibody (RIK-2), (N): L. plantarum S1-stimu-
lated with 2 lg/ml DR5/Fc chimera protein. The values shown are means (n = 3);
bars: ±S.D. * vs. (d): no treatment (P < 0.05), ** vs. (s): L. plantarum S1-stimulated
(P < 0.05). The ﬁgure represents results of one typical experiment of three
experiments performed.
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binant DR5/Fc chimera, which has a dominant negative function
against TRAIL receptors (Fig. 6C), or with a TRAIL-speciﬁc neutral-
izing mAb (Fig. 6D). Taken together, these results indicate that the
NK activity induced by L. plantarum-stimulation is mainly medi-
ated through TRAIL production derived from PBMC.
4. Discussion
Recently, increasing attention has focused on human recombi-
nant TRAIL and agonistic antibodies against TRAIL receptors as
promising anti-tumor agents [3,4]. On the other hand, the immune
surveillance role of endogenous TRAIL against malignant tumors
has been highlighted. Moreover, endogenous TRAIL plays an impor-
tant role in the inhibition of carcinogenesis [7]. Therefore, we tried
to ﬁnd agents that can produce endogenous TRAIL. In this manu-
script, we show for the ﬁrst time that lactobacillus treatment pro-
duces endogenous TRAIL from immune cells. The induction of
TRAIL expression is caused by L. plantarum at themRNA and protein
levels, resulting in the cell surface and the release soluble TRAIL.
Such effects were not shown by other bacteria tested (data not
shown). As the mechanism for the induction of TRAIL expression
by L. plantarum, we demonstrated that IFN-a and IFN-c contribute
to its expression; however, other mechanismsmay also exist. IFN-a
[20] and IFN-c [21] has been shown to up-regulate TRAIL transcrip-
tion through a site on the TRAIL gene promoter, which is consistent
with our result that L. plantarum increases TRAIL mRNA.
So far, it has been reported that lactobacilli enhance NK activity
to effectively attack malignant tumor cells in vitro and in vivo
[8,22]. However, little is known about the molecular mechanisms
underlying the NK activity. Here, we show for the ﬁrst time that
TRAIL is the key molecule causing the cytotoxicity induced by L.
plantarum against malignant tumor cells.
As the next step, we need to elucidate whether oral administra-
tion of L. plantarum also enhances the TRAIL-dependent NK activity
in vivo. L. plantarum did not show any cytotoxic effects against
PBMC (data not shown). Therefore, L. plantarum itself is supposed
to be safe. Moreover, we have previously reported that some ﬂavo-
noids, which are widely distributed in many fruits and vegetables,
up-regulate DR5 and enhance recombinant TRAIL-induced apopto-
sis in human malignant tumor cells [23,24]. We therefore raise a
possibility that the oral administration of L. plantarum and some
ﬂavonoids might have a beneﬁcial effect on prevention against
malignant tumors by activating the TRAIL-DR5 pathway.
In summary, we have demonstrated that L. plantarum enhances
the NK activity through endogenous TRAIL production. Our results
may lead to a novel strategy for caner prevention based on TRAIL.
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